
NeuroPace (NPCE) Stock Forecast & Price Target
NeuroPace (NPCE) Analyst Ratings
Bulls say
NeuroPace is viewed favorably because its RNS System is a differentiated, data-rich therapy that addresses a large, underpenetrated epilepsy market, with penetration still low despite over 10 years of approval history. The bullish case is supported by meaningful growth levers: 2023 growth of 44%, 2024 growth of 22%, and underlying 2025 RNS revenue growth of ~25%, alongside management’s indicated recovery to ~15% in 2027 and gross margins of 80%+. Additional upside comes from expanded indications such as IGE, pediatrics, and LGS, plus clinical catalysts and technology improvements like ECoG Assistant, remote programming, and next-generation devices that could improve adoption and support sustained profitability by end of 2027.
Bears say
NeuroPace is facing a fundamentally weaker commercial trajectory after 3Q26 sales of $23.1M fell below expectations and RNS revenue growth slowed to 1.4%, reflecting disruptions from sales leadership changes, field-team reorganization, and lost surgeon access after the SEEG transition. The company’s near-term outlook is further pressured by management’s reduced 2026 and 2027 sales estimates and lower EBITDA expectations, which underscore limited confidence in a quick recovery and suggest that execution problems may be more structural than transient. In addition, the FDA’s late July 2026 request for more evidence on the IGE PMA supplement, combined with concerns about competitive share loss to VNS and slower account recovery, leaves the stock dependent on clearer proof of durable commercial improvement.
This aggregate rating is based on analysts' research of NeuroPace and is not a guaranteed prediction by Public.com or investment advice.
NeuroPace (NPCE) Analyst Forecast & Price Prediction
Start investing in NeuroPace (NPCE)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About NeuroPace (NPCE) Forecast
NeuroPace (NPCE) Analyst Forecast & Price Prediction
Start investing in NeuroPace (NPCE)
Order type
Buy in
Order amount
Est. shares
0 shares